Extensive and widespread use of antimicrobial drugs led to the emergence of resistant strains of microorganisms. These microorganisms are no longer susceptible to the currently available antimicrobial drugs. Bacteria are acquiring resistance to all available antibiotics at a much faster rate than the introduction of new drugs and are posing a serious and imminent threat to public health. Moreover, antibiotic resistance can cross international boundaries and spread over the population easily, and many forms of resistance spread with remarkable speed.
Antimicrobial peptides (AMPs) are part of the armament that insects have developed to fight off pathogenic bacteria. The ability of natural occurring antimicrobial peptides to efficiently and selectively kill resistant bacteria strains has endured 250 million years of evolution and is the inspiration at the core of our technology. AMPs unique mechanism of action leads to a physical disturbance of the bacterial membrane, exerting a powerful antimicrobial effect. The bactericidal nature of the peptide activity prevents resistance, recurrence, and tolerance.
However, antimicrobial peptides are not stable and are highly prone to proteolytic degradation. This instability is the major obstacle that has hindered AMPs for therapeutic use and prevented the commercialization of these agents. Omnix’s technology is overcoming this obstacle with genetic-engineering; our agents are designed as highly potent and stable antibiotic agents against resistant bacteria. Omnix Medical’s scientific team has designed an arsenal of powerful and effective antibiotic compounds based on different AMPs, and our unique technology serves as a platform which allows for further peptides to be designed for therapeutic use.